These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12364634)

  • 1. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial.
    Choy EH; Panayi GS; Emery P; Madden S; Breedveld FC; Kraan MC; Kalden JR; Rascu A; Brown JC; Rapson N; Johnston JM
    Rheumatology (Oxford); 2002 Oct; 41(10):1142-8. PubMed ID: 12364634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients.
    Choy EH; Connolly DJ; Rapson N; Jeal S; Brown JC; Kingsley GH; Panayi GS; Johnston JM
    Rheumatology (Oxford); 2000 Oct; 39(10):1139-46. PubMed ID: 11035136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
    Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
    Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody.
    Choy EH; Chikanza IC; Kingsley GH; Corrigall V; Panayi GS
    Scand J Immunol; 1992 Aug; 36(2):291-8. PubMed ID: 1354392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments.
    Scheerens H; Su Z; Irving B; Townsend MJ; Zheng Y; Stefanich E; Chindalore V; Bingham CO; Davis JC
    Arthritis Res Ther; 2011; 13(5):R177. PubMed ID: 22029963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate.
    Moreland LW; Pratt PW; Mayes MD; Postlethwaite A; Weisman MH; Schnitzer T; Lightfoot R; Calabrese L; Zelinger DJ; Woody JN
    Arthritis Rheum; 1995 Nov; 38(11):1581-8. PubMed ID: 7488278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double blind, placebo controlled multicenter trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritis.
    Wendling D; Racadot E; Wijdenes J; Sibilia J; Flipo RM; Cantagrel A; Miossec P; Eschard JP; Macro M; Bertin P; Lioté F; Debiais F; Juvin R; Le Goff P; Masson C
    J Rheumatol; 1998 Aug; 25(8):1457-61. PubMed ID: 9712083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients.
    Goldberg D; Morel P; Chatenoud L; Boitard C; Menkes CJ; Bertoye PH; Revillard JP; Bach JF
    J Autoimmun; 1991 Aug; 4(4):617-30. PubMed ID: 1777012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis.
    van der Lubbe PA; Dijkmans BA; Markusse HM; Nässander U; Breedveld FC
    Arthritis Rheum; 1995 Aug; 38(8):1097-106. PubMed ID: 7639806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody.
    Horneff G; Burmester GR; Emmrich F; Kalden JR
    Arthritis Rheum; 1991 Feb; 34(2):129-40. PubMed ID: 1994909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis.
    Mason U; Aldrich J; Breedveld F; Davis CB; Elliott M; Jackson M; Jorgensen C; Keystone E; Levy R; Tesser J; Totoritis M; Truneh A; Weisman M; Wiesenhutter C; Yocum D; Zhu J
    J Rheumatol; 2002 Feb; 29(2):220-9. PubMed ID: 11838838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
    Kremer J; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Han J; Taylor P
    Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial.
    Choy EH; Hazleman B; Smith M; Moss K; Lisi L; Scott DG; Patel J; Sopwith M; Isenberg DA
    Rheumatology (Oxford); 2002 Oct; 41(10):1133-7. PubMed ID: 12364632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis.
    Hepburn TW; Totoritis MC; Davis CB
    Rheumatology (Oxford); 2003 Jan; 42(1):54-61. PubMed ID: 12509613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration.
    Reiter C; Kakavand B; Rieber EP; Schattenkirchner M; Riethmüller G; Krüger K
    Arthritis Rheum; 1991 May; 34(5):525-36. PubMed ID: 2025306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis.
    Tak PP; van der Lubbe PA; Cauli A; Daha MR; Smeets TJ; Kluin PM; Meinders AE; Yanni G; Panayi GS; Breedveld FC
    Arthritis Rheum; 1995 Oct; 38(10):1457-65. PubMed ID: 7575695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.